Insulin-like Growth Factors in Health and Disease

Abstract ▪ The insulin-like growth factor (IGF) family of peptides, binding proteins, and receptors are ubiquitous and important for normal human growth and development. Modern techniques including...

[1]  Brown Al,et al.  Insulin-like growth factor binding proteins: gene structure and expression. , 1992 .

[2]  R. Baxter,et al.  Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. , 1991, The Journal of clinical endocrinology and metabolism.

[3]  H. Werner,et al.  Insulinlike growth factors and their receptors as growth regulators in normal physiology and pathologic states , 1991, Trends in Endocrinology & Metabolism.

[4]  D. Barlow,et al.  The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus , 1991, Nature.

[5]  K. Takano,et al.  Effects of insulin-like growth factor-I on insulin and glucagon release from isolated perfused rat pancreas. , 1990, Endocrinologia japonica.

[6]  B. Burguera,et al.  The Insulin-Like Growth Factor-II/Mannose 6-Phosphate Receptor , 1989 .

[7]  J. Merryweather,et al.  Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia. , 1990, The Journal of biological chemistry.

[8]  M. Boes,et al.  Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart. , 1990, Endocrinology.

[9]  D. Clemmons,et al.  Insulin‐like growth factor (IGF) binding to human fibroblast and glioblastoma cells: The modulating effect of cell released IGF binding proteins (IGFBPs) , 1990, Journal of cellular physiology.

[10]  M. Boes,et al.  Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. , 1990, Endocrinology.

[11]  Simeon I. Taylor,et al.  Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. , 1990, The Journal of clinical investigation.

[12]  P. Sönksen,et al.  METABOLIC EFFECTS OF AN INSULIN‐LIKE FACTOR CAUSING HYPOGLYCAEMIA IN A PATIENT WITH A HAEMANGIOPERICYTOMA , 1990, Clinical endocrinology.

[13]  K. Polonsky,et al.  Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. , 1990, The Journal of clinical investigation.

[14]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[15]  J. Mersey,et al.  Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid. , 1989, The Journal of clinical endocrinology and metabolism.

[16]  E. Froesch,et al.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. , 1989, Acta endocrinologica.

[17]  M. Czech.  Signal transmission by the insulin-like growth factors , 1989, Cell.

[18]  R. Baxter,et al.  Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[19]  W. Daughaday,et al.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Ranke,et al.  Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. , 1989, Endocrinology.

[21]  S. Kornfeld,et al.  Mannose 6-phosphate receptors and lysosomal enzyme targeting. , 1989, The Journal of biological chemistry.

[22]  M. Pandian,et al.  Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. , 1989, The Journal of clinical endocrinology and metabolism.

[23]  M. Bayne,et al.  Characterization of the increased biological potency in BALB/C 3T3 cells of two analogs of human insulinlike growth factor I which have reduced affinity for the 28 K cell‐derived binding protein , 1989, Journal of cellular physiology.

[24]  P. Rotwein,et al.  Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. , 1988, The New England journal of medicine.

[25]  S. Lamberts,et al.  THERAPY OF ACROMEGALY WITH SANDOSTATIN: THE PREDICTIVE VALUE OF AN ACUTE TEST, THE VALUE OF SERUM SOMATOMEDIN‐C MEASUREMENTS IN DOSE ADJUSTMENT AND THE DEFINITION OF A BIOCHEMICAL ‘CURE’ , 1988, Clinical endocrinology.

[26]  K. Brismar,et al.  Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus , 1988, Journal of endocrinological investigation.

[27]  A. Barkan,et al.  Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. , 1988, The Journal of clinical endocrinology and metabolism.

[28]  S. Lamberts,et al.  SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. , 1987, The Journal of clinical endocrinology and metabolism.

[29]  W. Rutter,et al.  Insulin-like growth factor II receptor as a multifunctional binding protein , 1987, Nature.

[30]  R. Furlanetto,et al.  A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. , 1987, American journal of diseases of children.

[31]  W. Daughaday,et al.  Measurement of insulin-like growth factor I (IGF-I) responsiveness of fibroblasts of children with short stature: identification of a patient with IGF-I resistance. , 1987, The Journal of clinical endocrinology and metabolism.

[32]  W. Heizer,et al.  Use of plasma somatomedin-C/insulin-like growth factor I measurements to monitor the response to nutritional repletion in malnourished patients. , 1985, The American journal of clinical nutrition.

[33]  L. Phillips,et al.  Nutrition and somatomedin. XIII. Usefulness of somatomedin-C in nutritional assessment. , 1985, The American journal of medicine.

[34]  D. Styne,et al.  Growth hormone treatment for short stature. , 1983, The New England journal of medicine.

[35]  D. Clemmons,et al.  CHANGES IN CIRCULATING SOMATOMEDIN‐C LEVELS IN BROMOCRIPTINE‐TREATED ACROMEGALY , 1982, Clinical endocrinology.

[36]  E. Van Obberghen-Schilling,et al.  Stimulation of glucose incorporation and amino acid transport by insulin and an insulin-like growth factor in fibroblasts with defective insulin receptors cultured from a patient with leprechaunism. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Clemmons,et al.  Evaluation of acromegaly by radioimmunoassay of somatomedin-C. , 1979, The New England journal of medicine.

[38]  R. Furlanetto,et al.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. , 1977, The Journal of clinical investigation.

[39]  W. Daughaday,et al.  A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. , 1957, The Journal of laboratory and clinical medicine.

[40]  M. Rechler.  Insulin-like growth factor binding proteins. , 1993, Vitamins and hormones.

[41]  A. Ullrich,et al.  Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Chrétien,et al.  An infant with deletion of the distal long arm of chromosome 15 (q26.1----qter) and loss of insulin-like growth factor 1 receptor gene. , 1991, American journal of medical genetics.

[43]  A. Nairn,et al.  Protein phosphatases: recent progress. , 1991, Advances in second messenger and phosphoprotein research.

[44]  R. Koistinen,et al.  Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. , 1989, The Journal of clinical endocrinology and metabolism.

[45]  M. Ranke,et al.  Clinical relevance of serum measurements of insulin-like growth factors and somatomedin binding proteins. , 1988, Acta paediatrica Scandinavica. Supplement.

[46]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[47]  R. Rosenfeld,et al.  Clinical utility of insulin-like growth factor assays. , 1987, Pediatrician.

[48]  M. Rechler,et al.  Insulin-like growth factor receptors. , 1985, Journal of cell science. Supplement.